Lessons From 15 Years of Short Selling: How to Find Great Shorts

Whitney Tilson | |

There are all sorts of ways to make money on the short side.

​3 Reasons Why Amazon Invaded the U.S. Pharmacy Industry

Ong Kai Kiat | |

Amazon is like a shark, and this is what it feeds on.

NovaBay (NBY) Eyeing 60% Revenue Growth in 2017

Edward Kim | |

NovaBay Pharmaceuticals (NBY) hit positive cash flow in December 2016 as it promised, via sales of its Avenova antimicrobial eye care product. and has guided investors to 60% revenue growth in 2017.

Is Valeant Deeply Discounted or Damaged Goods?

Aswath Damodaran | |

I can no longer avert my eyes from this train wreck...

A Tight Bullish Pattern Is Forming on Wall Street

Adam Sarhan | |

Stocks rallied last week after nearly every major Central Bank in the world expressed caution.

EyeGate (EYEG) Shares + 60%: Enters Into Licensing Agreement with Valeant Pharma

Steve Kanaval | |

This partnership follows a 2015 agreement in which Valeant secured an exclusive worldwide license for its subsidiary to this product for uveitis. Valeant has maintained its right of last negotiation to license the product for other indications.

​All Eyes On Earnings...

Adam Sarhan | |

Until the next major catalyst, the bulls are in control.

Valeant Pharmaceuticals is a Test of Faith, Feedback and Fear

Aswath Damodaran | |

You can't have opportunity without danger...

​Stocks Soar On Trump Victory

Adam Sarhan | |

No doubt about it, it's been a wild week.

Is Deutsche Bank a Solid Contrarian Play?

Aswath Damodaran | |

Deutsche Bank may be a bit undervalued, but contrarians should still be cautious.

Discover: Trending Events

United Nations
Blockchain for Europe
Humanity 2.0
World Economic Forum